HALOZYME THERAPEUTICS INC

NASDAQ: HALO (Halozyme Therapeutics, Inc.)

最近更新时间: 12 Nov, 2024, 6:31PM

59.61

-1.48 (-2.42%)

前收盘价格 61.09
收盘价格 61.08
成交量 1,464,051
平均成交量 (3个月) 1,383,748
市值 7,584,001,536
市盈率 (P/E TTM) 19.74
预期市盈率 (P/E Forward) 10.91
价格/销量 (P/S) 6.52
股市价格/股市净资产 (P/B) 13.36
52周波幅
33.15 (-44%) — 65.53 (9%)
利润日期 31 Oct 2024
营业毛利率 41.43%
营业利益率 (TTM) 56.26%
稀释每股收益 (EPS TTM) 3.02
季度收入增长率 (YOY) 34.30%
季度盈利增长率 (YOY) 67.40%
总债务/股东权益 (D/E MRQ) 339.05%
流动比率 (MRQ) 10.36
营业现金流 (OCF TTM) 402.95 M
杠杆自由现金流 (LFCF TTM) 339.29 M
资产报酬率 (ROA TTM) 14.87%
股东权益报酬率 (ROE TTM) 111.83%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Halozyme Therapeutics, Inc. 看跌 看涨

AIStockmoo 评分

1.1
分析师共识 -0.5
内部交易活动 NA
价格波动 -0.5
技术平均移动指标 1.5
技术振荡指标 4.0
平均 1.13

相关股票

股票 市值 DY P/E(TTM) P/B
HALO 8 B - 19.74 13.36
EXEL 10 B - 23.24 4.43
BPMC 7 B - - 18.39
CORT 5 B - 41.02 8.18
NUVL 5 B - - 4.55
ADMA 4 B - 68.74 18.92

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

部门 Healthcare
行业 Biotechnology
投资方式 Small Growth
内部持股比例 1.06%
机构持股比例 100.80%
52周波幅
33.15 (-44%) — 65.53 (9%)
目标价格波幅
53.00 (-11%) — 73.00 (22%)
73.00 (JMP Securities, 22.46%) 购买
63.50 (6.53%)
53.00 (Piper Sandler, -11.09%) 保留
平均值 63.25 (6.11%)
总计 2 购买, 2 保留
平均价格@调整类型 54.22
公司 日期 目标价格 调整类型 价格@调整类型
Wells Fargo 13 Jan 2025 57.00 (-4.38%) 保留 54.14
HC Wainwright & Co. 10 Jan 2025 70.00 (17.43%) 购买 52.80
30 Dec 2024 68.00 (14.07%) 购买 47.99
Piper Sandler 10 Jan 2025 53.00 (-11.09%) 保留 52.80
04 Nov 2024 52.00 (-12.77%) 保留 58.47
JMP Securities 01 Nov 2024 73.00 (22.46%) 购买 57.15

该时间范围内无数据。

日期 类型 细节
08 Jan 2025 公告 Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
06 Jan 2025 公告 Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
30 Dec 2024 公告 Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
30 Dec 2024 公告 Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
30 Dec 2024 公告 Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
27 Nov 2024 公告 Halozyme to Present at Upcoming Investor Conferences
22 Nov 2024 公告 Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
18 Nov 2024 公告 Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
14 Nov 2024 公告 Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
31 Oct 2024 公告 HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
24 Oct 2024 公告 HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
23 Oct 2024 公告 Halozyme to Report Third Quarter 2024 Financial and Operating Results
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票